These findings suggest that VEGFC, VEGFR-3, and IGF1, integrated with clinical factors and EBV status, hold promise as non-invasive tools for risk assessment in NPC, potentially guiding personalized treatment approaches. This evidence concerns the gene FLT4 and nasopharyngeal carcinoma.